Vaccine Adjuvants Market

Vaccine Adjuvants Market by Product (Particulate, Emulsions, Pathogen, Saponin), Route of Administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Application (Research, Commercial) & Application Category - Global Forecast to 2027

Report Code: BT 4378 Aug, 2022, by marketsandmarkets.com

[214 Pages Report] The vaccine adjuvants market is projected to reach USD 1.6 billion by 2027 from USD 1.5 billion in 2022, at a CAGR of 1.7% during the forecast period. Growth in the vaccine adjuvants market can be attributed to factors such as the rising prevalence of infectious diseases and increasing use of adjuvants in vaccines from past three years.

Vaccine Adjuvants Market

To know about the assumptions considered for the study, Request for Free Sample Report

Global Vaccine Adjuvants Market Dynamics

Drivers: Rising prevalence of infectious diseases

The prevalence of infectious diseases, such as influenza, tuberculosis, malaria, and HIV, among others, has increased. The WHO estimates that seasonal influenza results in ~3 to 5 million cases of severe illness and ~290,000 to 650,000 respiratory deaths each year. In this regard, national influenza centers (NICs) and other national influenza laboratories from 74 countries have reported that the Global Influenza Surveillance and Response System (GISRS) laboratories tested more than 204,655 specimens for influenza between January 20, 2020, and February 20, 2020. Of these specimens, ~29% were found to be positive for the influenza virus. Influenza is one of the most common infectious diseases in the US.

Restraints: Skepticism about animal-sourced vaccine adjuvants and limitations on shark fishing

Squalene, derived from shark liver oil, is used in some adjuvants. This has led to the overfishing of sharks. As per the conservationist group Shark Allies, nearly 250,000 sharks need to be killed for the development of one COVID-19 vaccine dose for the global population.

Opportunities: Rising funding for vaccines and infectious disease research activities

With the emergence of COVID-19, government authorities and pharmaceutical & biotechnology companies have recognized the importance of research on infectious diseases.    In June 2022, the US announced a funding of USD 122 million to top Indian medical research institutes to prevent avoidable epidemics, early detection of disease threats, and rapid and effective response.

Challenges: Side effects and high toxicity of adjuvants

Vaccine adjuvants have various limitations, such as side effects and high toxicity, which are the major challenges hindering market growth. For instance, aluminum-based adjuvants have mild reactions after injection. Frequent occurrence of granulomas results in an increase in IgE production, and high levels of these salts cause neurological disorders and dialysis-associated dementia.

The adjuvant emulsions segment is projected to hold the dominant position during the forecast period:

On the basis on product, the global vaccine adjuvants market is segmented into adjuvant emulsions, pathogen components, saponin-based adjuvants, particulate adjuvants, and other adjuvants. The adjuvant emulsions segment is expected to remain dominant by 2027 woing to increase in number of adjuvanjted vaccines in  of adjuvant emulsions in COVID-19.

North America was the largest regional market for Vaccine adjuvants market in 2021.

The market is segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2021, North America accounted for the largest share of the market, and this trend is expected to continue during the forecast period. The increasing investments by companies in vaccine research and development and the presence of prominent market players in the US.

Vaccine Adjuvants Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Key Market Players

Key players in the market include GSK plc (UK), Dynavax Technologies (US), Novavax (US), Agenus Inc. (US), Croda International plc (UK), Seppic (France), OZ Biosciences (US), Phibro Animal Health Corporation (US), Associated British Foods plc (UK), InvivoGen (US), Merck KGaA (Germany), CSL Limited (Australia), Vertellus (US), Allergy Therapeutics (UK), Riboxx GmbH (Germany), CaPtivate Pharmaceuticals LLC (US), EuBiologics Co., Ltd. (South Korea), Pacific GeneTech Limited (US), Hawaii Biotech Inc. (US), Vaxine Pty Ltd. (Australia), Creative Diagnostics (US), LiteVax BV (Netherlands), Mukta Industries (India), Oncovir, Inc. (US), and TiterMax USA, Inc. (US).

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

Report Metric

Details

Market size available for years

2020–2027

Base year considered

2021

Forecast period

2022–2027

Forecast units

Value (USD)

Segments covered

Product, Route of Administration, Disease Type, Application, Application Category, and Region

Geographies covered

North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa

Companies covered

GSK plc (UK), Dynavax Technologies (US), Novavax (US), Agenus Inc. (US), Croda International plc (UK), Seppic (France), OZ Biosciences (US), Phibro Animal Health Corporation (US), Associated British Foods plc (UK), InvivoGen (US), Merck KGaA (Germany), CSL Limited (Australia), Vertellus (US), Allergy Therapeutics (UK), Riboxx GmbH (Germany), CaPtivatϵ Pharmaceuticals LLC (US), EuBiologics Co., Ltd. (South Korea), Pacific GeneTech Limited (US), Hawaii Biotech Inc. (US), Vaxine Pty Ltd. (Australia), Creative Diagnostics (US), LiteVax BV (Netherlands), Mukta Industries (India), Oncovir, Inc. (US), and TiterMax USA, Inc. (US).

This report categorizes the vaccine adjuvants market into the following segments and subsegments

By Product

  • Adjuvant Emulsions
  • Pathogen Components
  • Saponin-baased adjuvants
  • Particulate Adjuvants
  • Other Adjuvants

By Route of Administration

  • Intramuscular
  • Subcutaneous
  • Other Route of Administration

By Disease Type

  • Infectious Diseases
  • Cancer
  • Others

By Application

  • Research Applications
  • Commercial Applications

By Application Category

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
  • Middle East & Africa

Recent Developments

  • In October 2021, Dynavax Technologies (US) entered into a fully funded collaboration with the US Department of Defense to conduct a Phase 2 clinical trial for a plague vaccine adjuvanted with CpG 1018.
  • In February 2021, SK Bioscience (South Korea)and GSK plc (UK)entered into a collaboration for COVID-19 vaccine development.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 30)
    1.1 STUDY OBJECTIVES
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKET SCOPE
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED
    1.4 CURRENCY
    1.5 LIMITATIONS
    1.6 STAKEHOLDERS
    1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 35)
    2.1 RESEARCH APPROACH
          FIGURE 1 RESEARCH DESIGN
           2.1.1 PRIMARY RESEARCH
                    FIGURE 2 VACCINE ADJUVANTS MARKET: PRIMARY RESPONDENTS
    2.2 MARKET ESTIMATION METHODOLOGY
          FIGURE 3 VACCINE ADJUVANTS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2021
          FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2021
           2.2.1 INSIGHTS FROM PRIMARY EXPERTS
                    FIGURE 5 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
    2.3 MARKET GROWTH RATE PROJECTIONS
          FIGURE 6 VACCINE ADJUVANTS MARKET (DEMAND SIDE): GROWTH ANALYSIS OF DEMAND-SIDE FACTORS
    2.4 DATA TRIANGULATION
          FIGURE 7 DATA TRIANGULATION METHODOLOGY
    2.5 RESEARCH ASSUMPTIONS
    2.6 RISK ANALYSIS

3 EXECUTIVE SUMMARY (Page No. - 44)
    FIGURE 8 VACCINE ADJUVANTS MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)
    FIGURE 9 VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2022 VS. 2027 (USD MILLION)
    FIGURE 10 VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2022 VS. 2027 (USD MILLION)
    FIGURE 11 VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
    FIGURE 12 VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2022 VS. 2027 (USD MILLION)
    FIGURE 13 GEOGRAPHICAL SNAPSHOT OF VACCINE ADJUVANTS MARKET

4 PREMIUM INSIGHTS (Page No. - 48)
    4.1 VACCINE ADJUVANTS MARKET OVERVIEW
          FIGURE 14 RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET
    4.2 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY PRODUCT AND COUNTRY (2021)
          FIGURE 15 ADJUVANT EMULSIONS ACCOUNTED FOR LARGEST MARKET SHARE IN 2021
    4.3 VACCINE ADJUVANTS MARKET SHARE, BY PRODUCT, 2022 VS. 2027
          FIGURE 16 ADJUVANT EMULSIONS SEGMENT WILL CONTINUE TO DOMINATE MARKET IN 2027
    4.4 VACCINE ADJUVANTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
          FIGURE 17 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 51)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
          FIGURE 18 VACCINE ADJUVANTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
          TABLE 1 VACCINE ADJUVANTS MARKET: IMPACT ANALYSIS
           5.2.1 DRIVERS
                    5.2.1.1 Rising prevalence of infectious diseases
                    5.2.1.2 Increasing use of adjuvants in vaccines
                    5.2.1.3 Collaborations and partnerships among market players for development of vaccine adjuvants
                    5.2.1.4 Increasing number of COVID-19 vaccines in development pipeline
                                FIGURE 19 TOP LOCATIONS BASED ON NUMBER OF COVID-19 VACCINES IN DEVELOPMENT PIPELINE (AS OF OCTOBER 2021)
                    5.2.1.5 Increasing focus on immunization programs
           5.2.2 RESTRAINTS
                    5.2.2.1 Skepticism about animal-sourced vaccine adjuvants and limitations on shark fishing
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Rising funding for vaccines and infectious disease research activities
                                TABLE 2 NIH FUNDING FOR VACCINE RESEARCH, 2018–2022 (USD MILLION)
                    5.2.3.2 Development of plant-based vaccine adjuvants
           5.2.4 CHALLENGES
                    5.2.4.1 Side effects and high toxicity of adjuvants
    5.3 RANGES/SCENARIOS
          FIGURE 20 SCENARIOS BASED ON IMPACT OF UNCERTAINTIES ON GROWTH OF VACCINE ADJUVANTS MARKET
    5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
          FIGURE 21 REVENUE SHIFT AND NEW REVENUE POCKETS FOR VACCINE ADJUVANT PROVIDERS
    5.5 PRICING ANALYSIS
           5.5.1 AVERAGE SELLING PRICE OF PRODUCTS OFFERED BY MARKET PLAYERS
                    TABLE 3 AVERAGE SELLING PRICE OF PRODUCTS OFFERED BY MARKET PLAYERS
           5.5.2 AVERAGE SELLING PRICE TREND
    5.6 TECHNOLOGY ANALYSIS
           5.6.1 SUPERCRITICAL FLUID EXTRACTION TECHNOLOGY
    5.7 VALUE CHAIN ANALYSIS
          FIGURE 22 VALUE CHAIN ANALYSIS
    5.8 ECOSYSTEM ANALYSIS
          FIGURE 23 ECOSYSTEM ANALYSIS
          TABLE 4 SUPPLY CHAIN ECOSYSTEM
    5.9 PATENT ANALYSIS
          FIGURE 24 PATENT APPLICATIONS RELATED TO VACCINE ADJUVANTS MARKET, JANUARY 2012–AUGUST 2022
    5.10 KEY CONFERENCES AND EVENTS IN 2022–2023
           TABLE 5 LIST OF CONFERENCES AND EVENTS IN VACCINE ADJUVANTS MARKET
    5.11 REGULATORY ANALYSIS
           5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS IN DIFFERENT REGIONS/COUNTRIES
    5.12 PORTER’S FIVE FORCES ANALYSIS
           TABLE 6 PORTER’S FIVE FORCES ANALYSIS
           5.12.1 THREAT OF NEW ENTRANTS
           5.12.2 THREAT OF SUBSTITUTES
           5.12.3 BARGAINING POWER OF BUYERS
           5.12.4 BARGAINING POWER OF SUPPLIERS
           5.12.5 DEGREE OF COMPETITION
    5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
           5.13.1 KEY STAKEHOLDERS IN PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES AND THEIR INFLUENCE ON BUYING PROCESS
                    FIGURE 25 INFLUENCE OF STAKEHOLDERS IN PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES ON BUYING PROCESS OF VACCINE ADJUVANTS
           5.13.2 BUYING CRITERIA FOR VACCINE ADJUVANTS
                    FIGURE 26 BUYING CRITERIA FOR VACCINE ADJUVANTS

6 VACCINE ADJUVANTS MARKET, BY PRODUCT (Page No. - 67)
    6.1 INTRODUCTION
          TABLE 7 VACCINE ADJUVANTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
    6.2 ADJUVANT EMULSIONS
           6.2.1 ADJUVANT EMULSIONS FUNCTION BY GENERATING DEPOTS THAT TRAP ANTIGENS AT INJECTION SITE
                    TABLE 8 ADJUVANT EMULSIONS MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 9 NORTH AMERICA: ADJUVANT EMULSIONS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 10 EUROPE: ADJUVANT EMULSIONS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 11 ASIA PACIFIC: ADJUVANT EMULSIONS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    6.3 PATHOGEN COMPONENTS
           6.3.1 PROMINENT MARKET PLAYERS DEVELOPING BACTERIA-DERIVED ADJUVANTS—KEY FACTOR SUPPORTING MARKET GROWTH
                    TABLE 12 PATHOGEN COMPONENTS MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 13 NORTH AMERICA: PATHOGEN COMPONENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 14 EUROPE: PATHOGEN COMPONENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 15 ASIA PACIFIC: PATHOGEN COMPONENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    6.4 SAPONIN-BASED ADJUVANTS
           6.4.1 GROWING DEMAND FOR SAPONIN-BASED ADJUVANTS TO DRIVE MARKET
                    TABLE 16 SAPONIN-BASED ADJUVANTS MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 17 NORTH AMERICA: SAPONIN-BASED ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 18 EUROPE: SAPONIN-BASED ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 19 ASIA PACIFIC: SAPONIN-BASED ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    6.5 PARTICULATE ADJUVANTS
           6.5.1 MINERAL-BASED ADJUVANTS MOST WIDELY USED AMONG PARTICULATE ADJUVANTS
                    TABLE 20 PARTICULATE ADJUVANTS MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 21 NORTH AMERICA: PARTICULATE ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 22 EUROPE: PARTICULATE ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 23 ASIA PACIFIC: PARTICULATE ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    6.6 OTHER ADJUVANTS
          TABLE 24 OTHER VACCINE ADJUVANTS MARKET, BY REGION, 2020–2027 (USD MILLION)
          TABLE 25 NORTH AMERICA: OTHER VACCINE ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 26 EUROPE: OTHER VACCINE ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 27 ASIA PACIFIC: OTHER VACCINE ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

7 VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION (Page No. - 79)
    7.1 INTRODUCTION
          TABLE 28 VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
    7.2 INTRAMUSCULAR
           7.2.1 LARGEST AND FASTEST-GROWING MARKET SEGMENT
                    TABLE 29 ADVANTAGES AND DISADVANTAGES OF INTRAMUSCULAR ADMINISTRATION
                    TABLE 30 VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 31 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 32 EUROPE: VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 33 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION)
    7.3 SUBCUTANEOUS
           7.3.1 ADVANTAGES OFFERED BY SUBCUTANEOUS ADMINISTRATION TO DRIVE MARKET
                    TABLE 34 ADVANTAGES AND DISADVANTAGES OF SUBCUTANEOUS ADMINISTRATION
                    TABLE 35 VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 36 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 37 EUROPE: VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 38 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION)
    7.4 OTHER ROUTES OF ADMINISTRATION
          TABLE 39 VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2020–2027 (USD MILLION)
          TABLE 40 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 41 EUROPE: VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 42 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION)

8 VACCINE ADJUVANTS MARKET, BY DISEASE TYPE (Page No. - 87)
    8.1 INTRODUCTION
          TABLE 43 VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
    8.2 INFECTIOUS DISEASES
           8.2.1 INCREASED PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET
                    TABLE 44 VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 45 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 46 EUROPE: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 47 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
    8.3 CANCER
           8.3.1 INCREASING DEMAND FOR NOVEL CANCER VACCINES TO SUPPORT MARKET GROWTH
                    TABLE 48 VACCINE ADJUVANTS MARKET FOR CANCER, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 49 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR CANCER, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 50 EUROPE: VACCINE ADJUVANTS MARKET FOR CANCER, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 51 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR CANCER, BY COUNTRY, 2020–2027 (USD MILLION)
    8.4 OTHER DISEASES
          TABLE 52 VACCINE ADJUVANTS MARKET FOR OTHER DISEASES, BY REGION, 2020–2027 (USD MILLION)
          TABLE 53 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR OTHER DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 54 EUROPE: VACCINE ADJUVANTS MARKET FOR OTHER DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 55 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR OTHER DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)

9 VACCINE ADJUVANTS MARKET, BY APPLICATION (Page No. - 95)
    9.1 INTRODUCTION
          TABLE 56 VACCINE ADJUVANTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
    9.2 RESEARCH APPLICATIONS
           9.2.1 EXTENSIVE R&D FOR DEVELOPMENT OF VACCINE ADJUVANTS TO DRIVE MARKET
                    TABLE 57 VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 58 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 59 EUROPE: VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 60 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
    9.3 COMMERCIAL APPLICATIONS
           9.3.1 GROWING USE OF VACCINE ADJUVANTS FOR COMMERCIAL APPLICATIONS TO SUPPORT MARKET GROWTH
                    TABLE 61 VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 62 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 63 EUROPE: VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 64 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)

10 VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY (Page No. - 101)
     10.1 INTRODUCTION
             TABLE 65 VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION)
     10.2 HUMAN VACCINE ADJUVANTS
             10.2.1 INCREASE IN PARTNERSHIPS FOR DEVELOPMENT OF HUMAN VACCINE ADJUVANTS
                        TABLE 66 HUMAN VACCINE ADJUVANTS MARKET, BY REGION, 2020–2027 (USD MILLION)
                        TABLE 67 NORTH AMERICA: HUMAN VACCINE ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                        TABLE 68 EUROPE: HUMAN VACCINE ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                        TABLE 69 ASIA PACIFIC: HUMAN VACCINE ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
     10.3 VETERINARY VACCINE ADJUVANTS
             10.3.1 DEVELOPMENT OF ANIMAL VACCINES GOVERNED BY FEWER REGULATORY ASPECTS
                        TABLE 70 VETERINARY VACCINE ADJUVANTS MARKET, BY REGION, 2020–2027 (USD MILLION)
                        TABLE 71 NORTH AMERICA: VETERINARY VACCINE ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                        TABLE 72 EUROPE: VETERINARY VACCINE ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                        TABLE 73 ASIA PACIFIC: VETERINARY VACCINE ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

11 VACCINE ADJUVANTS MARKET, BY REGION (Page No. - 107)
     11.1 INTRODUCTION
             TABLE 74 VACCINE ADJUVANTS MARKET, BY REGION, 2020–2027 (USD MILLION)
     11.2 NORTH AMERICA
             FIGURE 27 NORTH AMERICA: VACCINE ADJUVANTS MARKET SNAPSHOT
             TABLE 75 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
             TABLE 76 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
             TABLE 77 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
             TABLE 78 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
             TABLE 79 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
             TABLE 80 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION)
             11.2.1 US
                        11.2.1.1 US dominates North American vaccine adjuvants market
                                      TABLE 81 US: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 82 US: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
                                      TABLE 83 US: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
                                      TABLE 84 US: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 85 US: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION)
             11.2.2 CANADA
                        11.2.2.1 Increasing government funding for vaccine research to drive market
                                      TABLE 86 CANADA: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 87 CANADA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
                                      TABLE 88 CANADA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
                                      TABLE 89 CANADA: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 90 CANADA: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION)
     11.3 EUROPE
             TABLE 91 EUROPE: VACCINE ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
             TABLE 92 EUROPE: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
             TABLE 93 EUROPE: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
             TABLE 94 EUROPE: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
             TABLE 95 EUROPE: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
             TABLE 96 EUROPE: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION)
             11.3.1 GERMANY
                        11.3.1.1 Growing funding from government organizations to drive market
                                      TABLE 97 GERMANY: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 98 GERMANY: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
                                      TABLE 99 GERMANY: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
                                      TABLE 100 GERMANY: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 101 GERMANY: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION)
             11.3.2 UK
                        11.3.2.1 Rising investments in vaccine development to boost market growth
                                      TABLE 102 UK: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 103 UK: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
                                      TABLE 104 UK: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
                                      TABLE 105 UK: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 106 UK: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION)
             11.3.3 FRANCE
                        11.3.3.1 Focus on new vaccine development to drive market
                                      TABLE 107 FRANCE: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 108 FRANCE: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
                                      TABLE 109 FRANCE: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
                                      TABLE 110 FRANCE: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 111 FRANCE: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION)
             11.3.4 ITALY
                        11.3.4.1 Increase in R&D for vaccines and government initiatives—key factors driving market
                                      TABLE 112 ITALY: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 113 ITALY: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
                                      TABLE 114 ITALY: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
                                      TABLE 115 ITALY: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 116 ITALY: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION)
             11.3.5 SPAIN
                        11.3.5.1 Increasing investments in vaccine development by government and private organizations to drive market
                                      TABLE 117 SPAIN: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 118 SPAIN: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
                                      TABLE 119 SPAIN: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
                                      TABLE 120 SPAIN: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 121 SPAIN: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION)
             11.3.6 REST OF EUROPE
                        TABLE 122 REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                        TABLE 123 REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
                        TABLE 124 REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,  2020–2027 (USD MILLION)
                        TABLE 125 REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                        TABLE 126 REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION)
     11.4 ASIA PACIFIC
             FIGURE 28 ASIA PACIFIC: VACCINE ADJUVANTS MARKET SNAPSHOT
             TABLE 127 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
             TABLE 128 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
             TABLE 129 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
             TABLE 130 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
             TABLE 131 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
             TABLE 132 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION)
             11.4.1 CHINA
                        11.4.1.1 Government support and strategic initiatives by key players to strengthen biotechnology sector
                                      TABLE 133 CHINA: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 134 CHINA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
                                      TABLE 135 CHINA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
                                      TABLE 136 CHINA: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 137 CHINA: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION)
             11.4.2 JAPAN
                        11.4.2.1 Government initiatives for vaccines to boost market
                                      TABLE 138 JAPAN: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 139 JAPAN: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
                                      TABLE 140 JAPAN: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
                                      TABLE 141 JAPAN: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 142 JAPAN: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION)
             11.4.3 INDIA
                        11.4.3.1 Growth of the biotechnology sector and development of new vaccines to drive market
                                      TABLE 143 INDIA: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 144 INDIA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
                                      TABLE 145 INDIA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
                                      TABLE 146 INDIA: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 147 INDIA: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION)
             11.4.4 REST OF ASIA PACIFIC
                        TABLE 148 REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                        TABLE 149 REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
                        TABLE 150 REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
                        TABLE 151 REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                        TABLE 152 REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION)
     11.5 LATIN AMERICA
             11.5.1 SURGE IN PHARMACEUTICAL AND BIOTECHNOLOGY RESEARCH— KEY FACTOR DRIVING MARKET
                        TABLE 153 LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                        TABLE 154 LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
                        TABLE 155 LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
                        TABLE 156 LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                        TABLE 157 LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION)
     11.6 MIDDLE EAST AND AFRICA
             11.6.1 INCREASING FUNDING AND GRANTS FOR VACCINE DEVELOPMENT TO DRIVE MARKET
                        TABLE 158 MIDDLE EAST AND AFRICA: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                        TABLE 159 MIDDLE EAST AND AFRICA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
                        TABLE 160 MIDDLE EAST AND AFRICA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
                        TABLE 161 MIDDLE EAST AND AFRICA: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                        TABLE 162 MIDDLE EAST AND AFRICA: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION)

12 COMPETITIVE LANDSCAPE (Page No. - 149)
     12.1 INTRODUCTION
     12.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
            FIGURE 29 VACCINE ADJUVANTS MARKET: STRATEGIES ADOPTED
     12.3 MARKET SHARE ANALYSIS
            FIGURE 30 VACCINE ADJUVANTS MARKET SHARE ANALYSIS, BY KEY PLAYER (2021)
            TABLE 163 VACCINE ADJUVANTS MARKET: DEGREE OF COMPETITION
     12.4 REVENUE ANALYSIS
            FIGURE 31 REVENUE ANALYSIS FOR KEY COMPANIES (2019–2021)
     12.5 COMPANY EVALUATION QUADRANT
             12.5.1 STARS
             12.5.2 EMERGING LEADERS
             12.5.3 PERVASIVE PLAYERS
             12.5.4 PARTICIPANTS
                        FIGURE 32 VACCINE ADJUVANTS MARKET: COMPANY EVALUATION MATRIX, 2021
     12.6 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS
             12.6.1 COMPANY FOOTPRINT (25 COMPANIES)
                        TABLE 164 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN VACCINE ADJUVANTS MARKET
             12.6.2 COMPANY PRODUCT FOOTPRINT (25 COMPANIES)
                        TABLE 165 PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS IN VACCINE ADJUVANTS MARKET
             12.6.3 COMPANY REGIONAL FOOTPRINT (25 COMPANIES)
                        TABLE 166 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN VACCINE ADJUVANTS MARKET
     12.7 COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES
             12.7.1 PROGRESSIVE COMPANIES
             12.7.2 STARTING BLOCKS
             12.7.3 RESPONSIVE COMPANIES
             12.7.4 DYNAMIC COMPANIES
                       FIGURE 33 VACCINE ADJUVANTS MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2021
     12.8 COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS
             TABLE 167 DETAILED LIST OF KEY STARTUP/SMES
             TABLE 168 COMPETITIVE BENCHMARKING OF KEY PLAYERS (STARTUPS/SMES)
     12.9 COMPETITIVE SCENARIO AND TRENDS
             12.9.1 PRODUCT LAUNCHES
                        TABLE 169 KEY PRODUCT LAUNCHES, JANUARY 2019–JULY 2022
             12.9.2 DEALS
                        TABLE 170 KEY DEALS, JANUARY 2019–JULY 2022
             12.9.3 OTHER KEY DEVELOPMENTS
                        TABLE 171 OTHER KEY DEVELOPMENTS, JANUARY 2019–JULY 2022

13 COMPANY PROFILES (Page No. - 164)
     13.1 KEY PLAYERS
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
             13.1.1 GSK PLC
                        TABLE 172 GSK PLC: BUSINESS OVERVIEW
                        FIGURE 34 GSK PLC: COMPANY SNAPSHOT (2021)
             13.1.2 DYNAVAX TECHNOLOGIES
                        TABLE 173 DYNAVAX TECHNOLOGIES: BUSINESS OVERVIEW
                        FIGURE 35 DYNAVAX TECHNOLOGIES: COMPANY SNAPSHOT (2021)
             13.1.3 NOVAVAX
                        TABLE 174 NOVAVAX: BUSINESS OVERVIEW
                        FIGURE 36 NOVAVAX: COMPANY SNAPSHOT (2021)
             13.1.4 AGENUS INC.
                        TABLE 175 AGENUS INC.: BUSINESS OVERVIEW
                        FIGURE 37 AGENUS INC.: COMPANY SNAPSHOT (2021)
             13.1.5 CRODA INTERNATIONAL PLC
                        TABLE 176 CRODA INTERNATIONAL PLC: BUSINESS OVERVIEW
                        FIGURE 38 CRODA INTERNATIONAL PLC: COMPANY SNAPSHOT (2021)
             13.1.6 SEPPIC (SUBSIDIARY OF AIR LIQUIDE GROUP)
                        TABLE 177 AIR LIQUIDE GROUP: BUSINESS OVERVIEW
                        FIGURE 39 AIR LIQUIDE: COMPANY SNAPSHOT (2021)
             13.1.7 PHIBRO ANIMAL HEALTH CORPORATION
                        TABLE 178 PHIBRO ANIMAL HEALTH CORPORATION: BUSINESS OVERVIEW
                        FIGURE 40 PHIBRO ANIMAL HEALTH CORPORATION: COMPANY SNAPSHOT (2020)
             13.1.8 SPI PHARMA (SUBSIDIARY OF ASSOCIATED BRITISH FOODS PLC)
                        TABLE 179 ASSOCIATED BRITISH FOODS PLC: BUSINESS OVERVIEW
                        FIGURE 41 ASSOCIATED BRITISH FOODS PLC: COMPANY SNAPSHOT (2021)
             13.1.9 CSL LIMITED
                        TABLE 180 CSL LIMITED: BUSINESS OVERVIEW
                        FIGURE 42 CSL LIMITED: COMPANY SNAPSHOT (2021)
             13.1.10 MERCK KGAA
                        TABLE 181 MERCK KGAA: BUSINESS OVERVIEW
                        FIGURE 43 MERCK KGAA: COMPANY SNAPSHOT (2021)
             13.1.11 OZ BIOSCIENCES
                        TABLE 182 OZ BIOSCIENCES: BUSINESS OVERVIEW
             13.1.12 INVIVOGEN
                        TABLE 183 INVIVOGEN: BUSINESS OVERVIEW
             13.1.13 ALLERGY THERAPEUTICS
                        TABLE 184 ALLERGY THERAPEUTICS: BUSINESS OVERVIEW
                        FIGURE 44 ALLERGY THERAPEUTICS: COMPANY SNAPSHOT (2020)
             13.1.14 VERTELLUS
                        TABLE 185 VERTELLUS: BUSINESS OVERVIEW
             13.1.15 EUBIOLOGICS CO., LTD.
                        TABLE 186 EUBIOLOGICS CO., LTD.: BUSINESS OVERVIEW
             13.1.16 PACIFIC GENETECH LIMITED
                        TABLE 187 PACIFIC GENETECH LIMITED: BUSINESS OVERVIEW
             13.1.17 HAWAII BIOTECH INC.
                        TABLE 188 HAWAII BIOTECH INC.: BUSINESS OVERVIEW
             13.1.18 RIBOXX GMBH
                        TABLE 189 RIBOXX GMBH: BUSINESS OVERVIEW
             13.1.19 CAPTIVATE PHARMACEUTICALS LLC
                        TABLE 190 CAPTIVATE PHARMACEUTICALS LLC: BUSINESS OVERVIEW
             13.1.20 VAXINE PTY LTD.
                        TABLE 191 VAXINE PTY LTD.: BUSINESS OVERVIEW
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
     13.2 OTHER COMPANIES
             13.2.1 CREATIVE DIAGNOSTICS
             13.2.2 LITEVAX BV
             13.2.3 MUKTA INDUSTRIES
             13.2.4 ONCOVIR, INC.
             13.2.5 TITERMAX USA, INC.

14 APPENDIX (Page No. - 208)
     14.1 DISCUSSION GUIDE
     14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     14.3 CUSTOMIZATION OPTIONS
     14.4 RELATED REPORTS
     14.5 AUTHOR DETAILS

This study involved four major activities in estimating the current size of the vaccine adjuvants market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive technical, market-oriented, and commercial study of the vaccine adjuvants market. The secondary sources used for this study include National Cancer Institute, National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI), National Institute of Allergy and Infectious Diseases (NIAID), United States Department of Health and Human Services, United States Agency for International Development, International Society for Vaccines, UNICEF, GAVI, PAHO, Medical Research Council, Annual Reports, SEC Filings, Investor Presentations, Expert Interviews, and MarketsandMarkets Analysis. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

Vaccine Adjuvants Market Size, and Share

*Others include sales managers, marketing managers, and product managers.

Note: Tiers are defined based on a company’s total revenue. As of 2021, Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the vaccine adjuvants market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and market have been identified through extensive secondary research
  • The revenues generated from the vaccine adjuvants and related products business of leading players have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Data Triangulation

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

  • To define, describe, and forecast the global vaccine adjuvants market based on the product, route of administration, disease type, application, application category, and region.
  • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, challenges, and opportunities).
  • To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall vaccine adjuvants market.
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders.
  • To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
  • To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies.
  • To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and R&D activities in the vaccine adjuvants market.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Company Information

An additional five company profiles

Report Code
BT 4378
Published ON
Aug, 2022
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Vaccine Adjuvants Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2022 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback